ANNUAL MEETING OF SHAREHOLDERS 2022
Greenfern Industries Limited is an entrepreneurial-led licensed medicinal cannabis and biotechnology company that also has operations spanning into the industrial hemp, hemp food and body care space.
Greenfern operates primarily from their medicinal cannabis research facility and hemp processing hub in Normanby, South Taranaki, with these facilities being powered by renewable energy generated by Greenfern’s own hydroelectric power station located adjacent to the facility on the Waingongoro River.
Greenfern is committed to environmentally friendly production of medicinal cannabis and hemp-based products. The medicinal cannabis research facility is designed around maximum efficiency and sustainability, being powered by renewable power and utilising an aeroponic production system which is renowned for its optimal water and nutrient efficiency. Greenfern’s hemp production also follows the same ethos. The hemp seed and its by-products are used for a range of different products from a high protein ingredient in a plant-based meat substitute, a hemp-based skin care range and hemp-based beverages amongst other things.
Greenfern is Toitū net carbonzero certified and is a B Corp Certified company.
Located on-site at our own hydroelectric power station. Our entire Taranaki operation is powered by clean green cost-price renewable hydro power with all the excess electricity sold back to the grid providing an additional source of revenue.
Our motivation is drawn from Theo’s story, a story of the difference that Cannabis extracts can make to the lives of those suffering from epilepsy and their families.
Greenfern Industries is part of a trio that has been awarded a further Bioresource Processing Alliance (BPA) grant to research high-value products from the by-products of hemp seed processing.
Greenfern is working with Hemp Connect and Callaghan Innovation on the project which, if it can be successfully commercialised, would see new and innovative food and cosmetic products made from what would otherwise be wastage from hemp seeds.
Patients in New Zealand, Australia and the Pacific Islands could soon have access to Syndros, one of only four Food and Drug Administration-approved (FDA) cannabinoid medicines.
Greenfern Industries (GFI) is looking to expand its pharmaceutical offering by considering a number of major international deals that would in part provide a pathway to a Schedule 3, over-the-counter registration using a novel cannabinoid medicine for its subsidiary, GFI Pharma. The deals would also provide authorisation for GFI Pharma to distribute Syndros.
Greenfern Industries continues to lead the way both locally and internationally, having been certified a Toitū net carbonzero organisation for the second year in a row. The certification means Greenfern remains New Zealand’s only Toitū net carbonzero certified medicinal cannabis and industrial hemp organisation.
Greenfern, founded on an unwavering commitment to environmental sustainability, is also the only B-Corp certified medicinal cannabis company in New Zealand.